Clinical TrialMay 26, 2026, 07:32 AM
BriaCell Phase 3 Study Gets 6th Positive DSMB Safety Nod
AI Summary
BriaCell Therapeutics announced that its independent Data Safety Monitoring Board (DSMB) has issued its sixth consecutive positive recommendation for the continuation of the pivotal Phase 3 Bria-ABC study. The DSMB found no safety concerns and recommended the study proceed without modifications. This study, which evaluates Bria-IMT plus an immune checkpoint inhibitor for patients with metastatic breast cancer, is being conducted under FDA Fast Track Designation, underscoring the significant unmet medical need.
Key Highlights
- DSMB issued its sixth consecutive positive recommendation for BriaCell's pivotal Phase 3 Bria-ABC study.
- The DSMB identified no safety concerns and recommended the study continue without modifications.
- The Phase 3 study evaluates Bria-IMT plus immune checkpoint inhibitor for metastatic breast cancer.
- The study is being conducted under FDA Fast Track Designation.
- DSMB meetings occur quarterly in accordance with the study protocol.
Price Impact
More from BCTX